|
|

SMARTREND WATCHING FOR POTENTIAL REBOUND IN SHARES OF SANOFI-AVENTIS AFTER ... - Zacks.com Zacks.com--Jun 16, 2011 (SmarTrend(R) News Watch via COMTEX) -- -Sanofi-Aventis- (NYSE:SNY) traded in a range yesterday that spanned from a low of $36.46 to a high of $37.35. Yesterday, the shares fell 4.35%, which took the trading range below the 3-day l - Date : Thu, 16 Jun 2011 12:38:51 GMT+00:00 |
Calls Purchased on Sanofi-Aventis - Benzinga Benzinga--Shares of -Sanofi-Aventis- (NYSE: SNY) are lower on the session by 2.97%, currently trading at $37.25. The stock has been moving largely higher over the past five months and is currently trading above the 200-day moving average. ... - Date : Wed, 15 Jun 2011 14:28:21 GMT+00:00 |
Sanofi-aventis Enters into Research Collaboration with Audion Therapeutics to ... - Reuters (press release) Reuters (press release)--Amsterdam, Netherlands - June 16, 2011 - Audion Therapeutics today announced that it has entered into a two-year agreement with Sanofi to to develop potential treatments for hearing loss through the optimization of small molecules - Date : Thu, 16 Jun 2011 06:01:24 GMT+00:00 |
Bullish Moving Average Cross by Sanofi-Aventis - Financial News Network Online Financial News Network Online---Sanofi-Aventis- (NYSE:SNY) shares have crossed bullishly above their 10-day moving average of $38.09 on a volume of 1 million shares. Swing traders may find an opportunity for a long position as such a crossover often sugge - Date : Tue, 14 Jun 2011 16:22:49 GMT+00:00 |
FTC eyes action to end pay-for-delay drug deals - Pittsburgh Tribune-Review Pittsburgh Tribune-Review--FTC Chairman Jon Leibowitz, pushing to abolish these deals, is studying how the agency may prohibit brand-name manufacturers such as Cephalon Inc. and -Sanofi Aventis- SA from paying generic-drug makers such as Watson Pharmaceut - Date : Sun, 12 Jun 2011 04:00:25 GMT+00:00 |
3 High Yielding European Stocks With Rising Earnings Estimates - Seeking Alpha Seeking Alpha---Sanofi-Aventis- (SNY) - -Sanofi-Aventis- engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product po - Date : Tue, 31 May 2011 12:59:28 GMT+00:00 |
What's Happening at ASCO This Year - Medscape Medscape--At the same session, results will be presented from another experimental drug in the same class, iniparib (-Sanofi-Aventis-), in patients with recurrent and platinum-resistant ovarian cancer (abstracts 5004 and 5005). ... - Date : Thu, 02 Jun 2011 19:55:10 GMT+00:00 |
3 Republicans vie for 2 council seats in Bridgewater - MyCentralJersey.com MyCentralJersey.com--Michael Pestorius, a former Navy officer and a director of operations at -Sanofi-Aventis-, hopes to defeat one of them. In his campaign materials, Pestorius has specifically targeted Rose, who was first appointed to the council in Jan - Date : Fri, 03 Jun 2011 02:43:36 GMT+00:00 |
Sanofi-aventis, DNDi collaborate to develop drugs for NTDs - Pharmaceutical Business Review Pharmaceutical Business Review---Sanofi-aventis- and Drugs for Neglected Diseases initiative (DNDi) have entered into a three-year research collaboration to generate new drugs for nine neglected tropical diseases (NTDs). The agreement covers kinetoplastid - Date : Mon, 30 May 2011 08:12:21 GMT+00:00 |
Sanofi takes fire for undisclosed financial relationships - Cardiovascular Business Cardiovascular Business--Members of the Senate Finance Committee are asking the FDA to delineate the steps taken to keep the citizen petition process transparent after it found that -Sanofi-Aventis- may have hidden financial relationships with societies a - Date : Thu, 02 Jun 2011 06:06:04 GMT+00:00 |